ArchiveAugust 2014

An alternative test for oligoclonal bands again

Hassan-Smith G, Durant L, Tsentemeidou A, Assi LK, Faint JM, Kalra S, Douglas MR, Curnow SJ.High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspectedmultiple sclerosis. J Neuroimmunol. 2014. pii: S0165-5728(14)00236-7. doi: 10.1016/j.jneuroim.2014.08.003. [Epub ahead of print] Cerebrospinal fluid (CSF) analysis is routinely used in the diagnostic...

Peripheral and central B cells involved in MS

Why does targeting systemic B cells in MS work? #MSResearch #MSBlog “The B cell remains top of the MS pop chart. It is the cell that is responsible for producing antibodies and providing memory for future antibody production in the case of infection. B cells can also act as so called professional antigen presenting cells that takes up antigens and display the antigens on their surface to...

Preliminary alemtuzumab survey results

When the results of a survey change the way you see the world; having progressive MS is like having a different disease. #MSBlog #MSResearch “Last week I did a ClinicSpeak post on ‘when to say no to alemtuzumab‘ and linked it to a survey. The preliminary results of the survey are quite surprising and a real eye-opener for me. Despite blogging on alemtuzumab for several years...

ClinicSpeak: life-threatening exacerbation on stopping natalizumab

Do we have enough evidence to stop MSers walking the natalizumab-rebound gauntlet? #ClinicSpeak #MSBlog #MSResearch “The tragic case report below highlights what we know already that when you stop natalizumab MS comes back with a vengeance. This poor lady had massive rebound and when they decided to restart natalizumab her conditioned go much worse. I assume they were worried about her...

CCSVI August

Leone MA, Raymkulova O, Lochner P, Bolamperti L, Rivadossi G, Stecco A, Zaccala G, Maggio M, Liboni W, Guido M, Coppo L, Imperiale D.Chronic cerebrospinal venous insufficiency is not associated with chronic venous disorders: A case-control study.Phlebology. 2014 Jul 31. pii: 0268355514544782. [Epub ahead of print] OBJECTIVES:To evaluate the relationship between chronic cerebrospinal venous...

Insoles don’t work?

Kalron A, Pasitselsky D, Greenberg-Abrahami M, Achiron A. Do textured insoles effect postural control and spatiotemporal parameters of gait and plantar sensation in people with multiple sclerosis? PM R. 2014 Aug 18. pii: S1934-1482(14)01327-6 BACKGROUND:Balance and gait deficits are common in people with multiple sclerosis (MS). Physical interventions directed at improving balance and walking...

ClinicSpeak: When to treat CIS?

When to start a DMT if you have CIS? #ClinicSpeak #MSBlog #MSResearch “I received an email query from a young woman who has had a clinically-isolated syndrome (CIS) and had difficulty getting onto an injectable 1st-line therapy because of confusion around the guidance from NHS England regarding eligibility for treatment. The guidance simply states that ‘Patients are eligible for...

MS register spots depression and anxiety

Jones KH, Jones PA, Middleton RM, Ford DV, Tuite-Dalton K, Lockhart-Jones H, Peng J, Lyons RA, John A, Noble JG. Physical Disability, Anxiety and Depression in People with MS: An Internet-Based Survey via the UK MS Register.PLoS One. 2014 Aug 25;9(8):e104604. INTRODUCTION: People with Multiple Sclerosis are known to have a relatively high prevalence of both anxiety and depression. Studies of...

Can we speed up the drug development process?

This is an Ebola virus and it is interesting that governments have approved the testing of an relatively-untested drug (it has not had the proper human trials) in people infected with this deadly virus…..However, when it comes to progressive MS, you have to wait until it goes through years of testing before you get a choice of whether you take the risk of a test drug in a trial...

ClinicSpeak: When to say no to alemtuzumab treatment?

When good intentions turn sour; tipping the risk:benefit scales the wrong way #ClinicSpeak #MSBlog #MSResearch “When I was a much younger MSologist I recall having to formulate mitoxantrone treatment guidelines for MSers with highly-active MS. At the time we had two competing protocols the monthly Edan protocol, for 6 months, for highly-active MSers who had failed the injectables therapies and...

Translate

Categories

Recent Posts

Recent Comments

Archives